Trials / Completed
CompletedNCT06030414
A Study to Determine the Tolerability of Intranasal LMN-301
A Phase 1, Single-site, Open-label Study to Determine the Safety and Tolerability of Single and Multiple Doses of Intranasally Administered LMN-301 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Lumen Bioscience, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
LMN-301 is to prevent infection by severe acute respiratory syndrome-corona virus (SARS-CoV-2) (the virus causing coronavirus disease of 2019 (COVID-19) in uninfected individuals. This study aims to assess whether the formulation will cause irritation when administered in the nose, and how long its protective effects will last. Thirty five healthy adult volunteers will participate in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | LMN-301 | Intranasally administered powder. |
Timeline
- Start date
- 2023-10-06
- Primary completion
- 2023-12-28
- Completion
- 2024-04-03
- First posted
- 2023-09-11
- Last updated
- 2025-07-30
- Results posted
- 2025-07-30
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT06030414. Inclusion in this directory is not an endorsement.